Latest Insights - page 70 | BiopharmaTrend

Sam Altman-backed Startup Partners with Microsoft to Enable the AI Infrastructure for Drug Discovery

A new five-year commercial agreement and go-to-market collaboration aims to merge 1910 Genetics' comprehensive computational and biological data with Microsoft’s HPC platform, Azure Quantum Elements. This union is expected to provide …

Continue ›››

A Busy Day for Ginkgo Bioworks

It is a remarkable day for Ginkgo Bioworks, a notable player in the field of synthetic biology, as the company announced today the acquisitions of two AI-driven drug discovery startups, …

Continue ›››

Curve Therapeutics Adds £10 Million for Its Intracellular Screening Platform

British Patient Capital has invested £10m in Southampton-based biotechnology firm Curve Therapeutics through its Future Fund: Breakthrough programme and co-investment initiative. This investment contributes to Curve’s Series A financing round, …

Continue ›››

14 Companies Using Quantum Theory To Accelerate Drug Discovery (Including 2 Going Public)

(Updated: 24.02.2024) Molecular mechanics (MM) is a traditional computational approach when it comes to modeling in synthetic organic chemistry, medicinal chemistry, and versatile aspects of drug design. However, MM methods …

Continue ›››

This Company Makes Quantum Computing Actually Useful

Quantum computing represents a monumental shift in the computational landscape, offering the potential to solve complex problems that are currently beyond the reach of classical computers. The principle behind quantum …

Continue ›››

How Precision Neuroscience and Drug Synergies Could Revolutionize Neurology

In a recent interview with Laurence Barker, a partner at SV Health Investors and a key figure in the Dementia Discovery Fund franchise, we discussed the evolving landscape of biotechnology …

Continue ›››

Using Quantum-Enhanced AI to Design Novel KRAS Inhibitors

In a collaborative effort, Zapata Computing (Zapata AI), together with Insilico Medicine, the University of Toronto, and St. Jude Children's Research Hospital, has made significant progress in the application of …

Continue ›››

A Novel Cancer Therapy Targeting KIF18A with AI-Designed Compound

Insilico Medicine, a leader in AI-driven drug discovery, has developed a new preclinical candidate, ISM9682, aimed at treating advanced solid tumors. This innovative compound, designed to inhibit the mitotic kinesin …

Continue ›››

Absci Initiates IND-Enabling Studies for ABS-101, Aiming for Enhanced Anti-TL1A Antibody Therapy

Absci has embarked on IND-enabling studies for ABS-101, an anti-TL1A antibody, leveraging its generative AI technology to streamline the development of biologic drugs. This initiative represents a key milestone in …

Continue ›››

This AI Startup Joins Forces With NVIDIA's BioNeMo to Boost Drug Discovery

Ultima Genomics Launches UG 100™ Sequencer to Advance Affordable Genomic Sequencing

Ultima Genomics, Inc., a pioneer in genomic sequencing technology, has introduced the UG 100™, a groundbreaking sequencer designed to significantly reduce the cost of genomic sequencing, thereby making the "$100 …

Continue ›››

Exscientia Launches New Clinical Study to Enhance Cancer Treatment Through AI

Exscientia plc, a UK-based AI-driven precision medicine company, has initiated a clinical study, EXCYTE-2, focusing on acute myeloid leukaemia (AML) patients. This observational study aims to refine the understanding of how …

Continue ›››